Pharsight

Cidara Theraps patents expiration

1. Rezzayo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8722619 CIDARA THERAPS Antifungal agents and uses thereof
Mar, 2032

(7 years from now)

US11654196 CIDARA THERAPS Dosing regimens for echinocandin class compounds
Mar, 2032

(7 years from now)

US9526835 CIDARA THERAPS Dosing regimens for echinocandin class compounds
Mar, 2033

(8 years from now)

US10702573 CIDARA THERAPS Dosing regimens for echinocandin class compounds
Mar, 2033

(8 years from now)

US11819533 CIDARA THERAPS Compositions and methods for the treatment of fungal infections
Jul, 2038

(14 years from now)

US11197909 CIDARA THERAPS Compositions and methods for the treatment of fungal infections
Jul, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11712459 CIDARA THERAPS Dosing regimens for treatment of fungal infections
Mar, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 22, 2030
New Chemical Entity Exclusivity (NCE) Mar 22, 2028
Generating Antibiotic Incentives Now (GAIN) Mar 22, 2033

Drugs and Companies using REZAFUNGIN ACETATE ingredient

NCE-1 date: 2032-03-22

Market Authorisation Date: 22 March, 2023

Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

REZZAYO family patents

Family Patents